Related Experiment Video
Updated: Feb 17, 2026

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications
Anna-Lena Volckmar1, Holger Sültmann2, Anja Riediger2
1Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Abstract:
Recently, many genome-wide profiling studies provided insights into the molecular make-up of major cancer types. The deeper understanding of these genetic alterations and their functional consequences led to the discovery of novel therapeutic opportunities improving clinical management of cancer patients. While tissue-based molecular patient stratification is the gold standard for precision medicine, it has certain limitations: Tissue biopsies are invasive sampling procedures carrying the risk of complications and may not represent the entire tumor due to underlying genetic heterogeneity. In this context, complementary characterization of genetic information in the blood of cancer patients can serve as minimal-invasive 'liquid biopsy'. Fragments of circulating cell-free DNA (cfDNA) are released from tissues of healthy individuals as well as cancer patients. The fraction of cfDNA that is released from primary tumors or metastases (i.e. circulating tumor DNA, ctDNA) represents genetic aberrations in cancer cells, which are a potential source for diagnostic, prognostic, and predictive biomarkers. Recent studies have demonstrated technical feasibility and clinical applications including detection of drug targets and resistance mutations as well as longitudinal monitoring of tumors under therapy. To this end, a variety of pre-analytical procedures for blood processing, isolation and quantification of cfDNA are being employed and several analytical methods and technologies ranging from PCR-based single locus assays to genome-wide approaches are available, which considerably differ in sensitivity, specificity, and throughput. However, broad implementation of ctDNA analysis in daily clinical practice requires a thorough understanding of theoretical, technical, and biological concepts and necessitates standardization and validation of pre-analytical and analytical procedures across different technologies. Here, we review the pertinent literature and discuss the advantages and limitations of available methodologies and their potential applications in molecular diagnostics.
Insights
Liquid biopsies using circulating tumor DNA (ctDNA) offer a minimally invasive alternative to tissue biopsies for cancer profiling. Standardization of ctDNA analysis is crucial for its clinical implementation in molecular diagnostics.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Genome-wide studies reveal cancer's molecular landscape, driving targeted therapies.
- Tissue biopsies for precision medicine face limitations like invasiveness and tumor heterogeneity.
- Liquid biopsies, analyzing circulating cell-free DNA (cfDNA), offer a minimally invasive approach.
Purpose of the Study:
- To review methodologies for analyzing circulating tumor DNA (ctDNA) in blood.
- To discuss the advantages and limitations of current ctDNA detection techniques.
- To explore the potential applications of ctDNA in molecular diagnostics.
Main Methods:
- Review of pertinent literature on cfDNA and ctDNA analysis.
- Discussion of pre-analytical procedures for blood processing and cfDNA isolation.
- Comparison of analytical methods for ctDNA detection, from PCR to genome-wide approaches.
Main Results:
- ctDNA analysis enables detection of drug targets and resistance mutations.
- Longitudinal monitoring of tumors under therapy is feasible with ctDNA.
- Available methodologies vary significantly in sensitivity, specificity, and throughput.
Conclusions:
- ctDNA analysis holds promise for cancer diagnostics, prognostics, and predictive biomarkers.
- Standardization and validation of pre-analytical and analytical procedures are essential for clinical adoption.
- Further understanding of theoretical, technical, and biological aspects is needed for broad implementation.
Related Concept Videos
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancers Originate from Somatic Mutations in a Single Cell
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer

